1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hirsch FR, Franklin WA, Gazdar AF and Bunn
PA Jr: Early detection of lung cancer: Clinical perspectives of
recent advances in biology and radiology. Clin Cancer Res. 7:5–22.
2001.PubMed/NCBI
|
3
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Ho C, Ramsden K, Zhai Y, Murray N, Sun S,
Melosky B and Laskin J: Less toxic chemotherapy improves uptake of
all lines of chemotherapy in advanced non-small-cell lung cancer: A
10-year retrospective population-based review. J Thorac Oncol.
9:1180–1186. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
van der Greef J: Perspective: All systems
go. Nature. 480:S872011. View
Article : Google Scholar : PubMed/NCBI
|
6
|
Wu J, Tang Q, Zhao S, Zheng F, Wu Y, Tang
G and Hahn SS: Extracellular signal-regulated kinase
signaling-mediated induction and interaction of FOXO3a and p53
contribute to the inhibition of nasopharyngeal carcinoma cell
growth by curcumin. Int J Oncol. 45:95–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Jiang WG, Ye L, Ji K, Frewer N, Ji J and
Mason MD: Inhibitory effects of Yangzheng Xiaoji on angiogenesis
and the role of the focal adhesion kinase pathway. Int J Oncol.
41:1635–1642. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gao L, Li Q, Jiang M, Liu C, Song Z, Bao
X, Shen Y, Liu G and Hu K: Combined therapy of percutaneous
cryoablation and traditional Chinese medicine can be a promising
strategy for elderly or advanced lung cancer patients based on a
retrospective clinical study. Cryobiology. 69:174–177. 2014.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhou L, Zuo Z and Chow MS: Danshen: An
overview of its chemistry, pharmacology, pharmacokinetics, and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zheng S, Ren Z, Zhang Y and Qiao Y:
Anti-inflammatory mechanism research of tanshinone II A by
module-based network analysis. Biomed Mater Eng. 24:3815–3824.
2014.PubMed/NCBI
|
11
|
Su CC, Chen GW and Lin JG: Growth
inhibition and apoptosis induction by tanshinone I in human colon
cancer Colo 205 cells. Int J Mol Med. 22:613–618. 2008.PubMed/NCBI
|
12
|
Gong Y, Li Y, Abdolmaleky HM, Li L and
Zhou JR: Tanshinones inhibit the growth of breast cancer cells
through epigenetic modification of Aurora A expression and
function. PLoS One. 7:e336562012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Li Y, Gong Y, Li L, Abdolmaleky HM and
Zhou JR: Bioactive tanshinone I inhibits the growth of lung cancer
in part via downregulation of Aurora A function. Mol Carcinog.
52:535–543. 2013. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Shang Q, Xu H and Huang L: Tanshinone IIA:
A promising natural cardioprotective agent. Evid Based Complement
Alternat Med. 2012:7164592012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chiu TL and Su CC: Tanshinone IIA induces
apoptosis in human lung cancer A549 cells through the induction of
reactive oxygen species and decreasing the mitochondrial membrane
potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
|
16
|
Lee CY, Sher HF, Chen HW, Liu CC, Chen CH,
Lin CS, Yang PC, Tsay HS and Chen JJ: Anticancer effects of
tanshinone I in human non-small cell lung cancer. Mol Cancer Ther.
7:3527–3538. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Hou J, Chong ZZ, Shang YC and Maiese K:
FOXO3a governs early and late apoptotic endothelial programs during
elevated glucose through mitochondrial and caspase signaling. Mol
Cell Endocrinol. 321:194–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhao GX, Xu LH, Pan H, Lin QR, Huang MY,
Cai JY, Ouyang DY and He XH: The BH3-mimetic gossypol and
noncytotoxic doses of valproic acid induce apoptosis by suppressing
cyclin-A2/Akt/FOXO3a signaling. Oncotarget. 6:38952–38966. 2015.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Chiacchiera F and Simone C: The
AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle.
9:1091–1096. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Kruger NJ: The bradford method for protein
quantitation. Methods Mol Biol. 32:9–15. 1994.PubMed/NCBI
|
22
|
Herzog CR, Blake DC Jr, Mikse OR,
Grigoryeva LS and Gundermann EL: FoxO3a gene is a target of
deletion in mouse lung adenocarcinoma. Oncol Rep. 22:837–843. 2009.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Blake DC Jr, Mikse OR, Freeman WM and
Herzog CR: FOXO3a elicits a pro-apoptotic transcription program and
cellular response to human lung carcinogen nicotine-derived
nitrosaminoketone (NNK). Lung Cancer. 67:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Liu HB, Gao XX, Zhang Q, Liu J, Cui Y, Zhu
Y and Liu YF: Expression and prognostic implications of FOXO3a and
Ki67 in lung adenocarcinomas. Asian Pac J Cancer Prev.
16:1443–1448. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zheng F, Tang Q, Wu J, Zhao S, Liang Z, Li
L, Wu W and Hann S: p38α MAPK-mediated induction and interaction of
FOXO3a and p53 contribute to the inhibited-growth and
induced-apoptosis of human lung adenocarcinoma cells by berberine.
J Exp Clin Cancer Res. 33:362014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ho TF and Chang CC: A promising ‘TRAIL’ of
tanshinones for cancer therapy. Biomedicine (Taipei). 5:232015.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Ma ZL, Zhang BJ, Wang DT, Li X, Wei JL,
Zhao BT, Jin Y, Li YL and Jin YX: Tanshinones suppress AURKA
through up-regulation of miR-32 expression in non-small cell lung
cancer. Oncotarget. 6:20111–20120. 2015.PubMed/NCBI
|
28
|
Gao H, Sun W, Zhao W, Hao W, Leung CH, Lu
J and Chen X: Total tanshinones-induced apoptosis and autophagy via
reactive oxygen species in lung cancer 95D cells. Am J Chin Med.
43:1265–1279. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Alagia A and Eritja R: siRNA and RNAi
optimization. Wiley Interdiscip Rev RNA. 7:316–329. 2016.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Shang YC, Chong ZZ, Hou J and Maiese K:
The forkhead transcription factor FOXO3a controls microglial
inflammatory activation and eventual apoptotic injury through
caspase 3. Curr Neurovasc Res. 6:20–31. 2009. View Article : Google Scholar : PubMed/NCBI
|